Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CFO Sells $164,596.05 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) CFO Pierre Gravier sold 2,139 shares of the business’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $76.95, for a total value of $164,596.05. Following the completion of the sale, the chief financial officer owned 90,310 shares of the company’s stock, valued at approximately $6,949,354.50. This trade represents a 2.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

PTC Therapeutics Stock Up 0.9%

Shares of PTCT stock opened at $77.53 on Friday. PTC Therapeutics, Inc. has a 12 month low of $35.95 and a 12 month high of $87.50. The company has a market cap of $6.22 billion, a PE ratio of 9.06 and a beta of 0.49. The business’s 50 day moving average is $76.61 and its two-hundred day moving average is $62.81.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.19) by $1.39. The business had revenue of $211.01 million during the quarter, compared to analysts’ expectations of $177.42 million. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. During the same period in the previous year, the company earned ($1.39) earnings per share. PTC Therapeutics’s revenue for the quarter was up 7.2% on a year-over-year basis. As a group, equities analysts expect that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on PTCT. Jefferies Financial Group raised their price target on PTC Therapeutics from $63.00 to $77.00 and gave the company a “buy” rating in a research report on Tuesday, October 28th. The Goldman Sachs Group raised their target price on PTC Therapeutics from $44.00 to $50.00 and gave the company a “sell” rating in a report on Wednesday, November 5th. Barclays upped their price target on PTC Therapeutics from $46.00 to $68.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 5th. Citigroup raised their price objective on shares of PTC Therapeutics from $50.00 to $75.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 5th. Finally, Royal Bank Of Canada lowered shares of PTC Therapeutics from an “outperform” rating to a “sector perform” rating and boosted their target price for the stock from $82.00 to $91.00 in a research report on Monday, December 1st. Nine research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $77.27.

Institutional Trading of PTC Therapeutics

A number of hedge funds have recently modified their holdings of PTCT. Smartleaf Asset Management LLC increased its position in shares of PTC Therapeutics by 101.3% during the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 236 shares during the period. Optiver Holding B.V. boosted its stake in PTC Therapeutics by 96.5% during the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 249 shares in the last quarter. Comerica Bank boosted its stake in PTC Therapeutics by 868.5% during the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 469 shares in the last quarter. IFP Advisors Inc increased its holdings in PTC Therapeutics by 68.1% in the 3rd quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 310 shares during the period. Finally, PNC Financial Services Group Inc. raised its stake in shares of PTC Therapeutics by 42.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 995 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 295 shares in the last quarter.

Key Stories Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Recent quarterly results showed an upside surprise (EPS and revenue beat), supporting valuation and reducing near-term execution risk. MarketBeat PTCT Summary
• Positive Sentiment: At least one independent researcher upgraded PTC from Hold to Buy (Wall Street Zen), and several firms have raised price targets in November — a bullish offset to otherwise muted analyst sentiment. Wall Street Zen Upgrade
• Neutral Sentiment: Analysts as a group still carry a consensus “Hold” rating on PTCT, indicating limited immediate upside from broker consensus alone. Analyst Consensus
• Neutral Sentiment: The company reported a routine inducement grant of 300 RSUs for a new non-executive hire under Nasdaq rules — small dilution and not material to fundamentals. PR Newswire
• Negative Sentiment: A director executed a large sale totaling $916,200, a notable insider disposition that can weigh on sentiment. Director Sale
• Negative Sentiment: Broad insider selling reported in multiple SEC Form 4 filings (CEO, CFO, EVP, VP, CAO and others sold shares in early January). The scale and breadth of executive sales likely represent profit-taking or diversification and can create short-term downward pressure until offset by fresh operational news. Representative SEC filing: SEC Form 4
• Negative Sentiment: EVP Lee Scott Golden and other insiders sold modest-to-large blocks (multiple transactions disclosed), reinforcing the headline of concentrated insider exits. InsiderTrades Alert

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.